Tower Research Capital (TRC)’s Regulus Therapeutics RGLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-6,384
| Closed | -$11.2K | – | 5525 |
|
|
2025
Q1 | $11.2K | Sell |
6,384
-4,802
| -43% | -$6.34K | ﹤0.01% | 3559 |
|
|
2024
Q4 | $17.7K | Buy |
11,186
+4,272
| +62% | +$6.56K | ﹤0.01% | 3293 |
|
|
2024
Q3 | $10.9K | Buy |
+6,914
| New | +$11.4K | ﹤0.01% | 3714 |
|
|
2024
Q2 | – | Sell |
-3,212
| Closed | -$9.25K | – | 5958 |
|
|
2024
Q1 | $9.25K | Buy |
3,212
+3,195
| +18,794% | +$5.21K | ﹤0.01% | 3877 |
|
|
2023
Q4 | $22 | Sell |
17
-3,569
| -100% | -$4.75K | ﹤0.01% | 5817 |
|
|
2023
Q3 | $4.91K | Sell |
3,586
-4,243
| -54% | -$6.15K | ﹤0.01% | 4793 |
|
|
2023
Q2 | $11.5K | Sell |
7,829
-4,002
| -34% | -$5.33K | ﹤0.01% | 3967 |
|
|
2023
Q1 | $10K | Buy |
11,831
+4,829
| +69% | +$6.38K | ﹤0.01% | 4398 |
|
|
2022
Q4 | $10K | Buy |
7,002
+6,660
| +1,947% | +$10.5K | ﹤0.01% | 4059 |
|
|
2022
Q3 | $0 | Sell |
342
-1,946
| -85% | -$3.5K | ﹤0.01% | 6412 |
|
|
2022
Q2 | $5K | Sell |
2,288
-556
| -20% | -$1.35K | ﹤0.01% | 5090 |
|
|
2022
Q1 | $8K | Buy |
2,844
+2,160
| +316% | +$5.62K | ﹤0.01% | 4612 |
|
|
2021
Q4 | $2K | Buy |
+684
| New | +$3.04K | ﹤0.01% | 5654 |
|
|
2021
Q3 | – | Sell |
-9,187
| Closed | -$75K | – | 6102 |
|
|
2021
Q2 | $75K | Buy |
9,187
+4,706
| +105% | +$52.5K | ﹤0.01% | 2671 |
|
|
2021
Q1 | $70K | Sell |
4,481
-7,618
| -63% | -$113K | ﹤0.01% | 2859 |
|
|
2020
Q4 | $163K | Buy |
12,099
+9,428
| +353% | +$69.2K | 0.01% | 1889 |
|
|
2020
Q3 | $14K | Sell |
2,671
-1,748
| -40% | -$11.5K | ﹤0.01% | 3970 |
|
|
2020
Q2 | $30K | Buy |
+4,419
| New | +$28.9K | ﹤0.01% | 3439 |
|
|
2019
Q3 | – | Sell |
-20
| Closed | – | – | 4452 |
|
|
2019
Q2 | $0 | Sell |
20
-95
| -83% | -$1.09K | ﹤0.01% | 4180 |
|
|
2019
Q1 | $1K | Sell |
115
-319
| -74% | -$3.47K | ﹤0.01% | 3610 |
|
|
2018
Q4 | $4K | Buy |
+434
| New | +$7.19K | ﹤0.01% | 3062 |
|
|
2018
Q3 | – | Sell |
-162
| Closed | -$13K | – | 4166 |
|
|
2018
Q2 | $13K | Buy |
162
+101
| +166% | +$8.36K | ﹤0.01% | 2669 |
|
|
2018
Q1 | $5K | Buy |
+61
| New | +$8.16K | ﹤0.01% | 2722 |
|
|
2017
Q2 | – | Sell |
-348
| Closed | -$68K | – | 3318 |
|
|
2017
Q1 | $68K | Buy |
348
+341
| +4,871% | +$64.9K | 0.01% | 604 |
|
|
2016
Q4 | $2K | Sell |
7
-17
| -71% | -$5.53K | ﹤0.01% | 3452 |
|
|
2016
Q3 | $9K | Buy |
+24
| New | +$9.87K | ﹤0.01% | 2157 |
|
|
2016
Q1 | – | Sell |
-6
| Closed | -$7K | – | 4789 |
|
|
2015
Q4 | $7K | Sell |
6
-22
| -79% | -$22.1K | ﹤0.01% | 2604 |
|
|
2015
Q3 | $22K | Buy |
28
+4
| +17% | +$4.11K | ﹤0.01% | 1651 |
|
|
2015
Q2 | $31K | Sell |
24
-75
| -76% | -$121K | ﹤0.01% | 1743 |
|
|
2015
Q1 | $202K | Buy |
+99
| New | +$215K | 0.03% | 407 |
|
|
2014
Q4 | – | Sell |
-20
| Closed | -$16K | – | 4576 |
|
|
2014
Q3 | $16K | Buy |
+20
| New | +$16.9K | ﹤0.01% | 2489 |
|
|
2014
Q2 | – | Sell |
-51
| Closed | -$55K | – | 4542 |
|
|
2014
Q1 | $55K | Buy |
51
+48
| +1,600% | +$53.2K | 0.01% | 1019 |
|
|
2013
Q4 | $3K | Sell |
3
-18
| -86% | -$15.5K | ﹤0.01% | 3865 |
|
|
2013
Q3 | $24K | Buy |
+21
| New | +$24.8K | ﹤0.01% | 2546 |
|
Other funds holding RGLS
Tower Research Capital (TRC)'s RGLS Position: Q2 2025 in Review
Tower Research Capital (TRC) sold out of Regulus Therapeutics (RGLS) in Q2 2025, closing a stake of 6,384 shares — an estimated $11.2K sold.
Tower Research Capital (TRC) first reported a position in RGLS in Q3 2013 and held it in 34 quarters. The position peaked at $202K in Q1 2015. 0 funds tracked by Wall St. Rank hold RGLS as of Q2 2025.
- Tower Research Capital (TRC) reported no remaining Regulus Therapeutics position as of Q2 2025 after selling out during the quarter.
- Tower Research Capital (TRC) sold 6,384 Regulus Therapeutics shares in Q2 2025, an estimated $11.2K.
- Tower Research Capital (TRC) first reported a position in Regulus Therapeutics in Q3 2013 and held it in 34 quarters.
- Tower Research Capital (TRC)'s Regulus Therapeutics position peaked at $202K in Q1 2015.
- 0 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q2 2025.
Based on Tower Research Capital (TRC)'s 13F filing for Q2 2025, filed 15 Aug 2025.